Sudation matinale Klaribac - heatherking26’s diary

Important Notice: The International Drugs.com database is in BETA release. This means it is still under development and may contain inaccuracies. It is a substitute for the expertise and judgment of your physician, pharmacist or other healthcare professional. It should not be construed to be appropriate or appropriate for you. Consult with your healthcare professional.

Always consult your healthcare provider to ensure the information provided.

Pharyngitis / Tonsillitis due to Streptococcus pyogenes in the treatment of mild to moderate infections caused by susceptible strains of pharyngitis Streptococcal Infections and the Prophylaxis of Rheumatic Fever in Patients with Streptococcal Infections and Clarithromycin in Patients with Nasopharyngeal Pharyngias rheumatic fever are not available at present). Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae. Bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae. Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR). Uncomplicated skin and skin structure infections caused by Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage). Disseminated Mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare (clarithromycin) Filmtab tablets in combination with amoxicillin and PREVACID (lansoprazole) or PRILOSEC (omeprazole) Delayed-Release Capsules, as triple therapy, are indicated for theylori of tests infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori. Filmtab tablets in combination with PRILOSEC (omeprazole) or TRITEC (ranitidine bismuth citrate) capsules are also indicated for the treatment of patients with active duodenal ulcer associated with H. pylori infection. However, regimens which contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because of the efficacy of treatment. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to clarithromycin is demonstrated, a non-clarithromycin-containing therapy is recommended. The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children (Filmtab Tablets and Granules for Oral Suspension) Pharyngitis / Tonsillitis due to Streptococcus pyogenes. Mycoplasma pneumoniae, Streptococcus pneumoniae, Pneumoniae pneumoniae, Pneumoniae pneumoniae, Pneumoniae pneumoniae, Pneumococcus pneumoniae (TWAR) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Acute otitis media due to Streptococcus pneumoniae, see Clinical Studies - Otitis Media . Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Mycobacterium intracellulare Adults (Filmtab Tablets) and Filmtab (clarithromycin extended release tablets) Infection caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenza Moraxella catarrhalis, Streptococcus pneumoniae Community-Acquired Pneumonia due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Streptococcus pneumoniae, Chlamydia pneumoniae (TWAR), or Mycoplasma pneumoniae.

Clarithromycin is contraindicated in patients with known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibiotics. Concomitant administration of clarithromycin and any of the following drugs is contraindicated: cisapride, pimozide, astemizole, terfenadine, and ergotamine or dihydroergotamine (see DRUG INTERACTIONS). There have been post-marketing reports of drug interactions when clarithromycin and / or erythromycin are coadministered with cisapride, pimozide, astemizole, or terfenadine resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes) most likely due to inhibition of metabolism of these drugs by erythromycin and clarithromycin. Fatalities have been reported.

General Prescribing Maclar in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of developing drug-resistant bacteria. Clarithromycin is principally excreted via the liver and kidney. Clarithromycin can be used without dosage adjustment to patients with hepatic impairment and normal renal function. However, in the presence of severe renal impairment with or without coexisting hepatic impairment, decreased dosage or prolonged dosing intervals may be appropriate. Clarithromycin in combination with ranitidine bismuth citrate therapy is not recommended in patients with creatinine clearance less than 25 mL / min. (See DOSAGE AND ADMINISTRATION.) Clarithromycin in combination with ranitidine bismuth citrate should not be used in patients with a history of acute porphyria. Exacerbation of symptoms of myasthenia gravis and new onset of symptoms of myasthenic syndrome reported in patients receiving clarithromycin therapy. PRECAUTIONS section of their package inserts. Carcinogenesis, Mutagenesis, Impairment of Fertility The following in vitro mutagenicity tests were conducted with clarithromycin: Salmonella / Mammalian Microsomes Test Bacterial Induced Mutation Frequency In Vitro Chromosome Aberration Test Rat Rat Hepatocyte DNA Synthesis Assay Mouse Lymphoma Assay Mouse Dominant Lethal Mouse Test tests had negative results except the In Vitro Chromosome Aberration Test which was weakly positive in one test and negative in another. In addition, a Bacterial Reverse-mutation Test (Ames Test) has been performed on clarithromycin metabolites with negative results. Fertility and reproduction studies have shown that daily doses of up to 160 mg / kg / day or number and viability of offspring. Plasma levels in rats after 150 mg / kg / day were 2 times the human serum levels. In the 150 mg / kg / day monkey studies, plasma levels were 3 times the human serum levels. When given orally at 150 mg / kg / day, clarithromycin was shown to produce embryonic loss in monkeys. This effect has been attributed to the maternal toxicity of this high dose drug. In rabbits, in utero fetal loss occurred at an intravenous dose of 33 mg / m², which is 17 times less than the maximum proposed human oral daily dose of 618 mg / m². Long-term studies in animals have been performed to evaluate the carcinogenic potential of clarithromycin. Pregnancy Teratogenic Effects Pregnancy Category C Four teratogenicity studies in rats (with oral doses up to 160 mg / kg / day administered during the period of major organogenesis) and oral doses up to 125 mg / kg (2 times the recommended maximum human dose based on mg / m 2) or intravenous doses of 30 mg / kg / day administered during gestation days 6 to 18 failed to report any teratogenicity of clarithromycin. Two additional oral studies in a different rat at similar doses and similar conditions showed a low incidence of cardiovascular abnormalities at doses of 150 mg / kg / day administered during gestation days 6 to 15. Plasma levels after 150 mg / kg / day were 2 times the human serum levels. Four studies in mice revealed a variable incidence of palate following oral doses of 1000 mg / kg / day (2 and 4 times the maximum recommended human dose based on mg / m 2, respectively) during gestation days 6 to 15. Cleft palate was also seen at 500 mg / kg / day. The 1000 mg / kg / day exposure resulted in plasma levels 17 times the human serum levels. In monkeys, an oral dose of 70 mg / kg / day was estimated at 2 times the human serum levels. There are no adequate and well-controlled studies in pregnant women. Clarithromycin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. (See WARNINGS.) Nursing Mothers It is not known whether or not clarithromycin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when clarithromycin is administered to a nursing woman. It is known that clarithromycin is excreted in the milk of lactating animals and that other drugs of this class are excreted in human milk. Preweaned rats, exposed via milk consumption for 150 mg / kg / day for 3 weeks, were not adversely affected. Pediatric Use Safety and effectiveness of clarithromycin in pediatric patients under 6 months of age have not been established. The safety of clarithromycin has not been studied in patients under the age of 20 months. Neonatal and juvenile animals tolerated clarithromycin in a manner similar to adult animals. Young erythrocytes, platelets, and leukocytes have been characterized by an increase in erythrocyte, platelet, and leukocyte density, kidney, thymus, and genitalia. Geriatric Use In a steady-state study in which healthy elderly subjects (age 65 to 81 years old) were given 500 mg every 12 hours, the maximum serum concentration and area under the curves of clarithromycin and 14-OH clarithromycin were increased compared to those carried in healthy young adults. These changes in pharmacokinetics are known in the art. In clinical trials, elderly patients did not have an increased incidence of adverse events when compared to younger patients. Dosage adjustment should be considered in elderly patients with severe renal impairment. (See WARNINGS and PRECAUTIONS.)

S: Streptococcus, Pneumococcus, Chlamydia, Legionella, Mycoplasma pneumonia, Listeria, Actinomyces, Campylobacter, H. pylori, Mycobacterium avium intracellulare.

The Cardiac Monitor, Model 1500 (CM-1500) continuously monitors the patient's physiological parameters. These parameters include: Bioelectrical Impedance, Heart Rate, Electrocardiogram (ECG) Amplitude, Photoplethysmography (PPG) Amplitude, Skin Temperature and Skin Humidity. The CM-1500 is intended for use in professional medical environments, i.e. hospitals, clinics and research institutions. The CM-1500 is a standalone device intended for desktop use, where operation is performed as uninterrupted patient monitoring.

To avoid adverse reactions and side effects, it is important to know the therapeutic indications of the drug, as well as its contraindications and precautions. The components of the drug may cause mild and serious side effects in patients who are hypersensitive to certain components of the drug. Talk to your doctor near you or online to find out exactly how to reduce the risk of side effects. Contact an emergency department for any of the following side effects:

The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as possible.

Opinion / decision on a Pediatric investigation plan (PIP): Clarithromycin (in combination with pantoprazole + amoxicillin), type decision :, therapeutic area :, PIP number: P / 0183/2019.

كلاريثروميسين هو مثبط قوي لأنزيم CYP3A4 ويمنع أيضا نقل بروتين ب. ج. . ب P-pg ((ABCB1 كلاريثروميسين هو مثبط قوي لأنزيم CYP3A4 الأدوية التي يتم تكسيرها في المقام الأول بواسطة إنزيم CYP3A4 قد يؤدي استخدام الكلاريثروميسين إلى زيادة هذه الأدوية في الدم (انظر أيضا موانع الاستعمال): مثل الكولشيسين colchicine: قم بتقليل جرعة الكولشيسين عند الاستعمال المتزامن مع الكلاريثروميسين في المرضى الذين لديهم وظائف الكبد والكلى طبيعية (ويمنع الاستعمال في حالة وجود قصور كبدي أو كلوي) الستاتينات Statins :. قم بتقليل جرعة أتورفاستاتين atorvastatin أو برافاستاتين pravastatin عند الاستعمال المتزامن مع كلاريثروميسين الأدوية الفموية الخافضة للسكر Oral hypoglycemic drugs و /. أو الأنسولين insulin يمكن أن يؤدي تناول كلاريثروميسين بالتزامن مع الأدوية الفموية الخافضة للسكر في الدم و / أو الأنسولين إلى نقص السكر في الدم بشكل كبير. أمثلة الأدوية الفموية الخافضة للسكر التي يتم تكسيرها بأنزيم CYP3A تشمل ناتيجلينيد nateglinide, بيوجليتازون pioglitazone ريباجلينيد repaglinide وروسيجليتازون rosiglitazone. مغلقات Calcium channel blockers قنوات الكالسيوم: قد يؤدي العلاج المتزامن مع مغلقات قنوات الكالسيوم إلى زيادة خطر انخفاض ضغط الدم وفشل الكلى والموت, مقارنة بالعلاج المتزامن لكل من مغلقات قنوات الكالسيوم والأزيثروميسين azithromycin, وهو دواء مشابه للكلاريثروميسين ولك ن ا يقوم بتثبيط أنزيم CYP3A4. لوحظ أن تناول الكلاريثروميسين مع عقار فيراباميل يسبب انخفاضا في ضغط الدم وانخفاض معدل ضربات القلب. كاربامازيبين Carbamazepine: قد يعمل كلاريثروميسين على مضاعفة مستوى الكاربامازيبين في الجسم عن طريق الحد من التخلص منه, مما قد يؤدي إلى أعراض سامة للكاربامازيبين, مثل الرؤية المزدوجة, وفقدان حركة الجسم الطوعية, والغثيان, وكذلك نقص صوديوم الدم. الكلاريثروميسين يؤدي الى استطالة الفاصل كيو تي QT مما يؤدي الى التفاعلات الدوائية التالية: البيموزيد pimozide والسيسابريد cisapride: يمنع استعماله مع بيموزيد pimozide مع سيسابريد cisapride (حيث ان كل منهم يسبب إطالة الفاصل كيو تي QT وأيضا يتم تكسيره بواسطة انزيم CYP3A4). يجب تجنب التناول المتزامن مع الأدوية التي تؤدي الى تطالة الفاصل كيو تي QT. الكويتيابين quetiapine: قد ينتج عن التناول المتزامن مع كويتيابين سميات مرتبطة بالكويتيابين, بما في ذلك المتلازمة الخبيثة للدواء المضاد للذهان neuroleptic malignant syndrome, إطالة الفاصل كيو تي QT prolongation, النعاس drowsiness, انخفاض ضغط الدم الوضعي (اثناء الوقوف) orthostatic hypotension, تغيرا في حالة الوعي. راقب بحذر لو تم تناول دواء الكلاري روميسين متزامنا مع أدوية قد تطيل فترة الفاصل كيو تي QT. تفاعلات أخرى الماكروليدات Macrolides: قد تزيد من تركيز الدم لمضادات فيتامين ك (مضادات التجلط مثل الوارفارين warfarin); يراعى رصد النسبة المعيارية الدولية (نسبة سيولة الدم INR). البنزوديازيبينات benzodiazepines: قد تزداد فترة ودرجة التهدئة (التخدير sedation) عند التناول المتزامن للكلاريثروميسين مع البنزوديازيبينات (مثل تريازولام triazolam, ميدازولام midazolam). الديجوكسين digoxin: قد يزيد الكلاري روميسين من مستويات الديجوكسين عن طريق تثبيط بروتين ب. ج. ب (P-gp)

الكلاريثروميسين Clarithromycin: هو من مجموعة المضادات الحيوية الماكروليدات macrolides يقوم الدواء بعمله كمضاد للبكتيريا عن طريق منع تكوين البروتين حيث يرتبط الدواء بشكل قابل للأنعكاس بالوحدة الفرعية 50S لريبوزوم البكتيريا الحساسة له وبالتالي يمنع تكوين البروتين المعتمد على الحمض النووي الريبوزي RNA ويمنع نمو البكتيريا.

مضادات الميكروبات Antimicrobial. مضادات البكتيريا Antibacterials. مثبطات تصنيع البروتين Protein synthesis inhibitors. التي ترتبط بالوحدة الفرعية الكبيرة 50 أس لريبوزوم بدائيات النوى Prokaryotic large ribosomal subunit 50S. مثبطات ترجمة بدائيات النوى Prokaryotic translation inhibitors. الماكروليدات Macrolides.

تفاقم حاد في التهاب الشعب الهوائية المزمن التهاب الجيوب الأنفية الفكي الحاد العدوى الفطرية. القرحة الهضمية. التهاب البلعوم أو اللوزتين. التهابات البلعوم الناتجة عن البكتيريا العقدية. الالتهاب الرئوي المكتسب من المجتمع. السعال الديكي. الالتهابات الجلدية. الوقاية من التهاب شغاف القلب.